DK3259599T3 - Biomarkører til diagnosticering og prognose af ektatiske hornhindelidelser - Google Patents

Biomarkører til diagnosticering og prognose af ektatiske hornhindelidelser Download PDF

Info

Publication number
DK3259599T3
DK3259599T3 DK16705123.4T DK16705123T DK3259599T3 DK 3259599 T3 DK3259599 T3 DK 3259599T3 DK 16705123 T DK16705123 T DK 16705123T DK 3259599 T3 DK3259599 T3 DK 3259599T3
Authority
DK
Denmark
Prior art keywords
biomarkers
prognosis
diagnosis
corneal disorders
ectatic
Prior art date
Application number
DK16705123.4T
Other languages
English (en)
Inventor
Gesto María Isabel Lema
Sánchez José Antonio Castillo
Moreiras Tomás Sobrino
Perez Francisco Campos
Original Assignee
Univ Santiago Compostela
Servizo Galego De Saude Sergas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Compostela, Servizo Galego De Saude Sergas filed Critical Univ Santiago Compostela
Application granted granted Critical
Publication of DK3259599T3 publication Critical patent/DK3259599T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK16705123.4T 2015-02-16 2016-02-16 Biomarkører til diagnosticering og prognose af ektatiske hornhindelidelser DK3259599T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382060.0A EP3056906A1 (en) 2015-02-16 2015-02-16 Biomarkers for diagnosis and prognosis of corneal ectasia
PCT/EP2016/053293 WO2016131840A1 (en) 2015-02-16 2016-02-16 Biomarkers for diagnosis and prognosis of corneal ectatic disorders

Publications (1)

Publication Number Publication Date
DK3259599T3 true DK3259599T3 (da) 2020-01-13

Family

ID=52589323

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16705123.4T DK3259599T3 (da) 2015-02-16 2016-02-16 Biomarkører til diagnosticering og prognose af ektatiske hornhindelidelser

Country Status (13)

Country Link
US (2) US10914746B2 (da)
EP (3) EP3056906A1 (da)
JP (1) JP6904908B2 (da)
KR (1) KR102495060B1 (da)
AU (1) AU2016221761A1 (da)
CA (1) CA2975951C (da)
DK (1) DK3259599T3 (da)
ES (1) ES2764456T3 (da)
HK (1) HK1248810A1 (da)
MX (2) MX2017010516A (da)
PT (1) PT3259599T (da)
SG (1) SG11201706249RA (da)
WO (1) WO2016131840A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6707239B1 (ja) 2019-03-13 2020-06-10 株式会社中京メディカル 円錐角膜判定装置及びプログラム
KR102287259B1 (ko) * 2019-08-27 2021-08-06 주식회사 비쥬웍스 원추 각막 진단 보조 시스템 및 이를 이용하는 방법
CN113009158B (zh) * 2021-04-30 2023-07-25 天津市眼科医院 中高度近视的辅助诊断标记物及其用途
US11406531B1 (en) * 2021-07-24 2022-08-09 Peter S. Hersh Method for the amelioration of ectatic and irregular corneal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7370969B2 (en) * 2004-03-31 2008-05-13 Nidek Co., Ltd. Corneal topography analysis system
GB0601959D0 (en) * 2006-01-31 2006-03-15 King S College London Sepsis test
US20070248970A1 (en) * 2006-03-24 2007-10-25 Eye Birth Defects Research Foundation Compositions and methods for detecting keratoconus
US20130058954A1 (en) * 2009-12-02 2013-03-07 The University Of Sydney Diagnostic and therapeutic methods for corneal ectasia following refractive surgery, keratoconus or pellucid degeneration
KR20130027281A (ko) * 2011-09-07 2013-03-15 (주)에스엘에스 원추각막 검사 방법 및 키트
WO2013107826A2 (en) * 2012-01-17 2013-07-25 Institut Pasteur Use of cellular biomarkers expression to diagnose sepsis among intensive care patients
WO2014106833A1 (en) * 2013-01-07 2014-07-10 Singapore Health Services Pte Ltd A process for identification of biomarkers for keratoconus progression

Also Published As

Publication number Publication date
SG11201706249RA (en) 2017-08-30
KR102495060B1 (ko) 2023-02-02
AU2016221761A1 (en) 2017-09-28
US10914746B2 (en) 2021-02-09
HK1248810A1 (zh) 2018-10-19
CA2975951A1 (en) 2016-08-25
MX2017010516A (es) 2018-06-15
KR20170138400A (ko) 2017-12-15
JP6904908B2 (ja) 2021-07-21
JP2018510651A (ja) 2018-04-19
EP3056906A1 (en) 2016-08-17
EP3259599B1 (en) 2019-10-02
US20210132084A1 (en) 2021-05-06
US20180067128A1 (en) 2018-03-08
ES2764456T3 (es) 2020-06-03
CA2975951C (en) 2023-02-14
PT3259599T (pt) 2020-01-27
MX2020006388A (es) 2020-09-17
EP3259599A1 (en) 2017-12-27
WO2016131840A1 (en) 2016-08-25
EP3608675A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3347015T3 (da) Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3577219T3 (da) Alfa-amylase-varianter
MA43958A (fr) Biomarqueurs copanlisib
DK3390422T3 (da) Krystalformer af lnt
DK3114235T3 (da) Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet
DK3455625T3 (da) Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK3529236T3 (da) Krystalformer af eravacyclin
HK1248810A1 (zh) 用於角膜擴張性疾病的診斷和預後的生物標記物
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3307323T3 (da) Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
DK3484475T3 (da) 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
DK3291831T3 (da) Rekombinant mykobakterie som et immunterapeutisk middel til behandling af cancer
DK3586840T3 (da) Mmp7-hæmmere til anvendelse i behandling af cystitis
DK3107554T3 (da) Antistof til påvirkning af kønsforholdet og metoder til anvendelse deraf